{"id":3812,"date":"2026-10-20T09:00:00","date_gmt":"2026-10-20T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3812"},"modified":"2026-10-21T20:36:21","modified_gmt":"2026-10-22T00:36:21","slug":"casdatifan-shows-activity-across-kidney-cancer-cohorts","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3812","title":{"rendered":"Casdatifan Shows Activity Across Kidney Cancer Cohorts"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Arcus Biosciences<\/p>\n

Event Type<\/strong><\/p>\n

Clinical Data Update (ARC-20 cohorts)<\/p>\n

Modality<\/strong><\/p>\n

Small molecule; oral HIF-2\u03b1 inhibitor<\/p>\n

Asset<\/strong><\/p>\n

Casdatifan (AB521)<\/p>\n

Target<\/strong><\/p>\n

HIF-2\u03b1<\/p>\n

Disease Area<\/strong><\/p>\n

Clear-cell renal cell carcinoma<\/p>\n

Summary<\/h4>\n

Arcus disclosed new ARC-20 cohort results for the HIF-2\u03b1 inhibitor casdatifan in clear-cell renal carcinoma. The breadth of activity supports further randomized trials, but comparisons with historical regimens cannot establish competitive superiority.<\/p>\n

This is a previously missed 20 October release recovered in the 36-hour reconciliation. In first-line casdatifan plus zimberelimab (n=30), confirmed response was 50% and 12-month landmark progression-free survival 69% after 11.5 months median follow-up. In second-line casdatifan plus cabozantinib (n=43), median PFS was 14.5 months after 21.3 months follow-up. Pooled late-line monotherapy cohorts (n=121; four doses) had median overall survival of 35 months, median PFS 13 months and confirmed response 36%.<\/p>\n

Deep Analysis<\/h4>\n

VHL-pathway dysregulation renders HIF-2\u03b1 a rational dependency in most clear-cell RCC. Casdatifan has a credible biological and clinical rationale across treatment lines, while the second-line randomized PEAK-1 trial directly tests additive benefit with cabozantinib. The late-line pooled result is notable for exposure across prior PD-1 and VEGFR treatment.<\/p>\n

The strongest counterargument is selection and cross-trial bias. ARC-20 cohorts are small, open-label and heterogeneous in dose and prior treatment; survival comparisons with belzutifan or cabozantinib trials mix different populations and follow-up. The first-line doublet differs from the planned PEAK-20 triple regimen, so activity of one cannot validate the other. Detailed anemia, hypoxia, discontinuation and dose-modification data are needed to determine whether deeper HIF-2\u03b1 inhibition preserves a usable therapeutic index.<\/p>\n

Company and Product Background<\/h4>\n

Casdatifan (AB521) is an oral HIF-2\u03b1 inhibitor. Loss of VHL-mediated HIF-2\u03b1 degradation activates angiogenic and survival programs in clear-cell renal cancer. Arcus retains most global rights; Taiho holds certain Asian rights excluding China.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Fact:<\/strong> new cohort readouts span first-, second- and later-line settings, with no randomized efficacy comparison yet.<\/li>\n
  • Company claim:<\/strong> casdatifan could become a backbone therapy; that remains a trial hypothesis.<\/li>\n
  • Upgrade:<\/strong> positive PEAK-1 randomized PFS\/OS with manageable class toxicity. Downgrade:<\/strong> failed comparator-adjusted outcome or high treatment-limiting hypoxia\/anemia.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: the data justify broad registration testing but do not yet displace an approved HIF-2\u03b1 inhibitor or immunotherapy\/TKI regimen. The phase 3 comparator result is the key value inflection.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: Positive, uncertain. Confidence in Facts: High. Confidence in Interpretation: Moderate\u2013Low. The direction score describes the evidence at this stage. It does not imply clinical approval, treatment readiness or commercial outcome.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Arcus disclosed new ARC-20 cohort results for the HIF-2\u03b1 inhibitor casdatifan in clear-cell renal carcinoma. The breadth of activity supports further randomized trials, but comparisons with historical regimens cannot establish competitive superiority.<\/p>\n","protected":false},"author":1,"featured_media":3826,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1138,1134,1135,1137,1136],"class_list":["post-3812","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-arc-20","tag-arcus-biosciences","tag-casdatifan","tag-clear-cell-renal-cell-carcinoma","tag-hif-2"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3812"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3812\/revisions"}],"predecessor-version":[{"id":3831,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3812\/revisions\/3831"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3826"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}